secwatch.observer — SEC 8-K summary
======================================

Issuer:     NextCure, Inc. (NXTC)
CIK:        0001661059
Form:       8-K
Filed at:   2021-08-05T23:59:59+00:00
Accession:  0001104659-21-100794
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NextCure Q2 net loss $18M; cash $249.5M; trials NC318/NC410/NC762 on track
--------------------------------------------------------------------------

- Net loss of $18.0M for Q2 2021 vs $14.5M in Q2 2020; R&D $11.9M, G&A $6.0M.
- Cash, equivalents & marketable securities $249.5M as of June 30, 2021; funded into H2 2023.
- NC318 Phase 2 update expected Q4 2021; dosing revised to 800 mg weekly; NSCLC cohort resumed.
- NC410 initial Phase 1 data expected Q4 2021; NC762 Phase 1 started, data mid-2022.
- CLIA-validated assay for S15+ patient selection available for NC318 trial.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1661059/000110465921100794/0001104659-21-100794-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1661059/000110465921100794/tm2124228d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-21-100794

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer